Evidence map›Paper›PMID 31928967›Full record

ArticleiScience2020

Predicting Human Clinical Outcomes Using Mouse Multi-Organ Transcriptome.

Satoshi Kozawa, Fumihiko Sagawa, Satsuki Endo, Glicia Maria De Almeida, Yuto Mitsuishi, Thomas N Sato

Open access · goldAbstract read
In one paragraph

Article in iScience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 3 countries.

Satoshi KozawaKarydo TherapeutiX, Inc., Kyoto, Japan; ERATO Sato Live Bio-Forecasting Project, Kyoto, Japan; The Thomas N. Sato BioMEC-X Laboratories, Advanced Telecommunications Research Institute International, 2-2-2 Hikaridai, Seika-cho, Soraku-gun, Kyoto 619-0288, Japan.
Fumihiko SagawaKarydo TherapeutiX, Inc., Kyoto, Japan; ERATO Sato Live Bio-Forecasting Project, Kyoto, Japan; The Thomas N. Sato BioMEC-X Laboratories, Advanced Telecommunications Research Institute International, 2-2-2 Hikaridai, Seika-cho, Soraku-gun, Kyoto 619-0288, Japan.
Satsuki EndoKarydo TherapeutiX, Inc., Kyoto, Japan; ERATO Sato Live Bio-Forecasting Project, Kyoto, Japan; The Thomas N. Sato BioMEC-X Laboratories, Advanced Telecommunications Research Institute International, 2-2-2 Hikaridai, Seika-cho, Soraku-gun, Kyoto 619-0288, Japan.
Glicia Maria De AlmeidaKarydo TherapeutiX, Inc., Kyoto, Japan.
Yuto MitsuishiKarydo TherapeutiX, Inc., Kyoto, Japan.
Thomas N SatoKarydo TherapeutiX, Inc., Kyoto, Japan; ERATO Sato Live Bio-Forecasting Project, Kyoto, Japan; The Thomas N. Sato BioMEC-X Laboratories, Advanced Telecommunications Research Institute International, 2-2-2 Hikaridai, Seika-cho, Soraku-gun, Kyoto 619-0288, Japan; Biomedical Engineering, Cornell University, Ithaca, NY, USA; Centenary Institute, Sydney, Australia; V-iClinix Laboratory, Nara Medical University, Nara, Japan. Electronic address: island1005@gmail.com.
Advanced Telecommunications Research Institute International · JPCornell University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Approximately 90% of pre-clinically validated drugs fail in clinical trials owing to unanticipated clinical outcomes, costing over several hundred million US dollars per drug. Despite such critical importance, translating pre-clinical data to clinical outcomes remain a major challenge. Herein, we designed a modality-independent and unbiased approach to predict clinical outcomes of drugs. The approach exploits their multi-organ transcriptome patterns induced in mice and a unique mouse-transcriptome database "humanized" by machine learning algorithms and human clinical outcome datasets. The cross-validation with small-molecule, antibody, and peptide drugs shows effective and efficient identification of the previously known outcomes of 5,519 adverse events and 11,312 therapeutic indications. In addition, the approach is adaptable to deducing potential molecular mechanisms underlying these outcomes. Furthermore, the approach identifies previously unsuspected repositioning targets. These results, together with the fact that it requires no prior structural or mechanistic information of drugs, illustrate its versatile applications to drug development process.

Indexed as

Biocomputational MethodBioinformaticsBiological SciencesComputational BioinformaticsPharmacoinformatics

Identifiers

PMID31928967
PMCPMC7033637
OpenAlexW2998782948

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.